Paolo Romanelli is a Dermatology physician affiliated with University of Miami. OpenAlex indexes 177 publications with 3,614 citations (h-index 31).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1475 NW 12th Ave
Miami, FL 331361002
Telephone
305-243-8693Registry record last updated 7 Feb 2013.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202510 payments
- Novartis Pharmaceuticals CorporationProgram year20258 payments
- ABBVIE INC.Program year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
37.9%Interleukin-17A Antagonist11.1%Cosentyx Sensoready (2 Pens)75%Cosentyx (2 Syringes)25%Part D<11 patientsInterleukin-23 Antagonist7.5%Tremfya51%Skyrizi Pen49%Part D<11 patients+ 4 more classes in this area
Dermatology
29.3%Corticosteroid15.8%Triamcinolone Acetonide78%Fluocinolone Acetonide22%Part D<11 patientsInterleukin-4 Receptor alpha Antagonist10.9%Dupixent Syringe51%Dupixent Pen49%Part D<11 patients+ 1 more class in this area
Sensory organs
12.8%Corticosteroid12.8%Clobetasol Propionate78%Betamethasone Dipropionate22%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes
Endocrinology Diabetes and Metabolism Case Reports
2023 - Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus
Orphanet Journal of Rare Diseases
2023 - Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
American Journal of Clinical Dermatology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Carlos Singer
University of Miami
Kara Cavuoto, MD
University of Miami
Sixto Arias, MD
University of Miami
Richard Kardon, DO
University of Miami
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”